[Tamoxifen, endometrial cancer and levonorgestrel intra-uterine device].
Although the adjuvant tamoxifen benefit/risk rate is unquestionable in breast cancer treatment, the increase of endometrial cancer in chemoprevention is about to be a real problem. In the studies currently published metrorragia in the main signal. Levonogestrel intra-uterine device has not proved its efficacy for the decrease of this risk.